Amendment: SEC Form SC 13D/A filed by Janux Therapeutics Inc.

10/25/24 5:28:42 PM ET

$JANX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JANX alert in real time by email

SC 13D/A 1 tm2426876d1_sc13da.htm SC 13D/A

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Janux Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

47103J 105

(CUSIP Number)

Jay Lichter, Ph.D.

Avalon Ventures

1134 Kline Street

La Jolla, California 92037

(858) 348-2180

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

October 23, 2024

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 47103J 105
1.	Names of Reporting Persons Avalon Ventures XI, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) WC
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 1,828,127 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 1,828,127 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,828,127 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 3.5% (3)
14.	Type of Reporting Person (See Instructions) PN

(1)

This Schedule 13D is filed by Avalon Ventures XI, L.P. (“Avalon Ventures”), Avalon BioVentures SPV I, L.P. (“ABV SPV”), Avalon BioVentures I, LP (“ABV I”), Avalon Ventures XI GP LLC (“Avalon XI GP”), ABV SPV I GP LLC (“ABV SPV GP”), Avalon BioVentures GP, LLC (“ABV GP”), Kevin Kinsella (“Kinsella”), Richard Levandov (“Levandov”), Braden Bohrmann (“Bohrmann”), Jay Lichter, Ph.D (“Lichter”), Tighe Reardon (“Reardon”), Sergio G. Duron, Ph.D. (“Duron”) and Sanford J. Madigan, Ph.D. (“Madigan” and, with Avalon Ventures, ABV SPV, ABV I, Avalon XI GP, ABV SPV GP, ABV GP, Kinsella, Levandov, Bohrmann, Lichter, Reardon and Duron, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Shares are held by Avalon Ventures. Avalon XI GP is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Kinsella, Levandov, Bohrmann and Lichter are the managing members of Avalon XI GP and share voting and investment power with respect to the shares held by Avalon Ventures.

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Avalon BioVentures SPV I, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) WC
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 1,866,576 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 1,866,576 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,866,576 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 3.6% (3)
14.	Type of Reporting Person (See Instructions) PN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Shares are held by ABV SPV. ABV SPV GP is the general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV. Lichter and Reardon are the managing members of ABV SPV GP and share voting and investment power with respect to the shares held by ABV SPV.

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Avalon BioVentures I, LP
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) WC
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 354,118 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 354,118 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 354,118 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 0.7% (3)
14.	Type of Reporting Person (See Instructions) PN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Shares are held by ABV I. ABV GP is the general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I. Lichter, Reardon, Duron and Madigan are the managing members of ABV GP and share voting and investment power with respect to the shares held by ABV I.

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Avalon Ventures XI GP LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 1,828,127 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 1,828,127 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,828,127 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 3.5% (3)
14.	Type of Reporting Person (See Instructions) OO

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons ABV SPV I GP LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 1,866,576 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 1,866,576 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,866,576 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 3.6% (3)
14.	Type of Reporting Person (See Instructions) OO

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Avalon BioVentures GP, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 354,118 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 354,118 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 354,118 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 0.7% (3)
14.	Type of Reporting Person (See Instructions) OO

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Kevin Kinsella
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 1,828,127 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 1,828,127 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,828,127 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 3.5% (3)
14.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,828,127 shares of Common Stock held by Avalon Ventures. Avalon XI GP is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Kinsella, Levandov, Bohrmann and Lichter are the managing members of Avalon XI GP and share voting and investment power with respect to the shares held by Avalon Ventures.

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Richard Levandov
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 5,651 shares
		8.	Shared Voting Power 1,828,127 shares (2)
		9.	Sole Dispositive Power 5,651 shares
		10.	Shared Dispositive Power 1,828,127 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,833,778 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 3.5% (3)
14.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Braden Bohrmann
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 0
		8.	Shared Voting Power 1,828,127 shares (2)
		9.	Sole Dispositive Power 0
		10.	Shared Dispositive Power 1,828,127 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,828,127 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 3.5% (3)
14.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Jay Lichter, Ph.D.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 41,497 shares (2)
		8.	Shared Voting Power 4,048,821 shares (3)
		9.	Sole Dispositive Power 41,497 shares (2)
		10.	Shared Dispositive Power 4,048,821 shares (3)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,090,318 shares (2) (3)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 7.8% (4)
14.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 35,423 shares of Common Stock issuable within 60 days of the date of the filing of this Schedule 13D upon exercise of stock options held by Lichter.

(3)

Includes (i) 1,828,127 shares of Common Stock held by Avalon Ventures; (ii) 1,866,576 shares of Common Stock held by ABV SPV; and (iii) 354,118 shares of Common Stock held by ABV I. Avalon XI GP is the general partner of Avalon Ventures. Kinsella, Levandov, Bohrmann and Lichter are the managing members of Avalon XI GP and share voting and investment power with respect to the shares held by Avalon Ventures. ABV SPV GP is the general partner of ABV SPV. Lichter and Reardon are the managing members of ABV SPV GP and share voting and investment power with respect to the shares held by ABV SPV. ABV GP is the general partner of ABV I. Lichter, Reardon, Duron and Madigan are the managing members of ABV GP and share voting and investment power with respect to the shares held by ABV I.

(4)

This percentage is calculated based on the sum of (i) 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 35,423 shares of Common Stock issuable within 60 days of the date of the filing of this Schedule 13D upon exercise of stock options, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Tighe Reardon
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 298,582 shares (2)
		8.	Shared Voting Power 2,220,694 shares (3)
		9.	Sole Dispositive Power 278,566 shares (2)
		10.	Shared Dispositive Power 2,220,694 shares (3)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,519,276 shares (2) (3)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 4.8% (4)
14.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 180,722 shares of Common Stock issuable upon the exercise of stock options held by Reardon that are vested or will vest within 60 days of the date of the filing of this Schedule 13D. Also includes 20,016 shares of Common Stock issuable upon early exercise of stock options held by Reardon that will not vest within 60 days of the date of the filing of this Schedule 13D, for which he is considered to have voting, but not dispositive, power.

(3)

Includes (i) 1,866,576 shares of Common Stock held by ABV SPV and (ii) 354,118 shares of Common Stock held by ABV I. ABV SPV GP is the general partner of ABV SPV. Lichter and Reardon are the managing members of ABV SPV GP and share voting and investment power with respect to the shares held by ABV SPV. ABV GP is the general partner of ABV I. Lichter, Reardon, Duron and Madigan are the managing members of ABV GP and share voting and investment power with respect to the shares held by ABV I.

(4)

This percentage is calculated based on the sum of (i) 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 200,738 shares of Common Stock issuable within 60 days of the date of the filing of this Schedule 13D upon exercise of stock options, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Sergio G. Duron, Ph.D.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 51,068 shares
		8.	Shared Voting Power 354,118 shares (2)
		9.	Sole Dispositive Power 51,068 shares
		10.	Shared Dispositive Power 354,118 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 405,186 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 0.8% (3)
14.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 354,118 shares of Common Stock held by ABV I. ABV GP is the general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I. Lichter, Reardon, Duron and Madigan are the managing members of ABV GP and share voting and investment power with respect to the shares held by ABV I.

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

CUSIP No. 47103J 105
1.	Names of Reporting Persons Sanford Madigan, Ph.D.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x (1)
3.	SEC Use Only
4.	Source of Funds (See Instructions) AF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ¨
6.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		7.	Sole Voting Power 59,680 shares
		8.	Shared Voting Power 354,118 shares (2)
		9.	Sole Dispositive Power 59,680 shares
		10.	Shared Dispositive Power 354,118 shares (2)
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 413,798 shares (2)
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
13.	Percent of Class Represented by Amount in Row (11) 0.8% (3)
14.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)

This percentage is calculated based on 52,164,498 shares of common stock outstanding as of August 5, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024, as adjusted to reflect the exercise of stock options described herein and as further adjusted pursuant to SEC Rule 13d-3.

Explanatory Note: This Amendment No. 6 (“Amendment No. 6”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on June 25, 2021 and amended on November 16, 2023, March 4, 2024, June 5, 2024, September 16, 2024 and October 22, 2024 (the “Original Schedule 13D”) filed on behalf of Avalon Ventures XI, L.P. (“Avalon Ventures”), Avalon BioVentures SPV I, L.P. (“ABV SPV”), Avalon BioVentures I, LP (“ABV I”), Avalon Ventures XI GP LLC (“Avalon XI GP”), ABV SPV I GP LLC (“ABV SPV GP”), Avalon BioVentures GP, LLC (“ABV GP”), Kevin Kinsella (“Kinsella”), Richard Levandov (“Levandov”), Braden Bohrmann (“Bohrmann”), Jay Lichter, Ph.D (“Lichter”), Tighe Reardon (“Reardon”), Sergio G. Duron, Ph.D. (“Duron”) and Sanford J. Madigan, Ph.D. (“Madigan” and, with Avalon Ventures, ABV SPV, ABV I, Avalon XI GP, ABV SPV GP, ABV GP, Kinsella, Levandov, Bohrmann, Lichter, Reardon and Duron, collectively, the “Reporting Persons”) relates to the common stock, $0.001 par value per share (the “Common Stock”), of Janux Therapeutics, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used but not defined herein have the meanings given to such terms in the Original Schedule 13D.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Statement is hereby amended and restated as follows:

(a)– (b).

The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of October 24, 2024:

Reporting Persons	Shares Held Directly		Sole Voting Power		Shared Voting Power		Sole Dispositive Power		Shared Dispositive Power		Beneficial Ownership		Percentage of Class (6)
Avalon Ventures (1)		1,828,127				1,828,127				1,828,127		1,828,127		3.5	%
ABV SPV (2)		1,866,576				1,866,576				1,866,576		1,866,576		3.6	%
ABV I (3)		354,118				354,118				354,118		354,118		0.7	%
Avalon XI GP (1)						1,828,127				1,828,127		1,828,127		3.5	%
ABV SPV GP (2)						1,866,576				1,866,576		1,866,576		3.6	%
ABV GP (3)						354,118				354,118		354,118		0.7	%
Kinsella (1)						1,828,127				1,828,127		1,828,127		3.5	%
Levandov (1)		5,651		5,651		1,828,127		5,651		1,828,127		1,833,778		3.5	%
Bohrmann (1)						1,828,127				1,828,127		1,828,127		3.5	%
Lichter (1) (2) (3) (4)		41,497		41,497		4,048,821		41,497		4,048,821		4,090,318		7.8	%
Reardon (2) (3) (5)		298,582		298,582		2,220,694		278,566		2,220,694		2,519,276		4.8	%
Duron (3)		51,068		51,068		354,118		51,068		354,118		405,186		0.8	%
Madigan (3)		59,680		59,680		354,118		59,680		354,118		413,798		0.8	%

(1)

(2)

Includes 1,866,576 shares of Common Stock held by ABV SPV. ABV SPV GP is the general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV. Lichter and Reardon are the managing members of ABV SPV GP and share voting and investment power with respect to the shares held by ABV SPV.

(3)

Includes 354,118 shares of Common Stock held by ABV I. ABV GP is general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I. Lichter, Reardon, Duron and Madigan are the managing members of ABV GP and share voting and investment power with respect to the shares held by ABV I.

(4)

Includes 35,423 shares of Common Stock issuable within 60 days of the date of the filing of this Schedule 13D upon exercise of stock options held by Lichter.

(5)

(6)

(c)

Schedule A sets forth all transactions with respect to the shares of Common Stock effected since the most recent amendment to this Schedule 13D by any Reporting Person and is incorporated herein by reference.

(d)

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

(e)

Not applicable.

Item 7.

Material to be Filed as Exhibits

Item 7 of the Statement is hereby amended and supplemented as follows:

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 25, 2024

AVALON VENTURES XI, L.P.		AVALON VENTURES XI GP LLC

By:	/s/ Tighe Reardon	By:	/s/ Tighe Reardon
	Name: Tighe Reardon		Name: Tighe Reardon
	Title: Authorized Signer		Title: Authorized Signer


AVALON BIOVENTURES SPV I, L.P.		ABV SPV I GP LLC

By:	/s/ Tighe Reardon	By:	/s/ Tighe Reardon
	Name: Tighe Reardon		Name: Tighe Reardon
	Title: Authorized Signer		Title: Authorized Signer


AVALON BIOVENTURES I, LP		AVALON BIOVENTURES GP, LLC

By:	/s/ Tighe Reardon	By:	/s/ Tighe Reardon
	Name: Tighe Reardon		Name: Tighe Reardon
	Title: Authorized Signer		Title: Authorized Signer


/s/ Kevin Kinsella		/s/ Tighe Reardon
Kevin Kinsella		Tighe Reardon


/s/ Richard Levandov		/s/ Sergio Duron
Richard Levandov		Sergio G. Duron, Ph.D.


/s/ Braden Bohrmann		/s/ Sanford Madigan
Braden Bohrmann		Sanford Madigan, Ph.D.


/s/ Jay Lichter
Jay Lichter, Ph.D.

	ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

SCHEDULE A

Transaction	Reporting Person	Date		No. Shares		Weighted Average Price ($)		Low Price ($)		High Price ($)
Open Market Sale of Common Stock	Avalon Ventures		10/23/2024		161,123	$	50.67	$	50.10	$	51.09
Open Market Sale of Common Stock	ABV I		10/23/2024		31,212	$	50.67	$	50.10	$	51.09
Open Market Sale of Common Stock	ABV SPV		10/23/2024		164,512	$	50.67	$	50.10	$	51.09
Open Market Sale of Common Stock	Avalon Ventures		10/23/2024		34,838	$	51.53	$	51.11	$	52.10
Open Market Sale of Common Stock	ABV I		10/23/2024		6,748	$	51.53	$	51.11	$	52.10
Open Market Sale of Common Stock	ABV SPV		10/23/2024		35,571	$	51.53	$	51.11	$	52.10
Open Market Sale of Common Stock	Avalon Ventures		10/23/2024		26,114	$	52.81	$	52.11	$	53.09
Open Market Sale of Common Stock	ABV I		10/23/2024		5,059	$	52.81	$	52.11	$	53.09
Open Market Sale of Common Stock	ABV SPV		10/23/2024		26,662	$	52.81	$	52.11	$	53.09
Open Market Sale of Common Stock	Avalon Ventures		10/23/2024		21,597	$	53.36	$	53.12	$	53.59
Open Market Sale of Common Stock	ABV I		10/23/2024		4,184	$	53.36	$	53.12	$	53.59
Open Market Sale of Common Stock	ABV SPV		10/23/2024		22,052	$	53.36	$	53.12	$	53.59
Open Market Sale of Common Stock	Duron		10/23/2024		6,806	$	51.44	$	51.44	$	51.44
Open Market Sale of Common Stock	Madigan		10/23/2024		7,954	$	51.34	$	51.34	$	51.34
Open Market Sale of Common Stock	Reardon		10/23/2024		13,039	$	51.05	$	51.05	$	51.05
Open Market Sale of Common Stock (1)	Lichter		10/24/2024		4,921	$	53.37	$	53.32	$	53.71
Open Market Sale of Common Stock (2)	Reardon		10/24/2024		20,570	$	52.23	$	51.73	$	52.71
Open Market Sale of Common Stock (2)	Reardon		10/24/2024		1,190	$	52.77	$	52.76	$	52.84

(1)

Immediately prior to the sales, Lichter received 930, 930, 2,231 and 631 shares of Common Stock upon the exercise of stock options at purchase prices of $10.73, $13.22, $17.00 and $39.80, respectively, for an aggregate purchase price of $85,314.30.

(2)

Immediately prior to the sales, Reardon received 12,232, 3,556 and 5,972 shares of Common Stock upon the exercise of stock options at purchase prices of $10.59, $14.02 and $20.24, respectively, for an aggregate purchase price of $300,216.35.

Exhibit(s):

A	Joint Filing Agreement

Get the next $JANX alert in real time by email

Date	Price Target	Rating	Analyst
12/3/2024	$82.00 → $100.00	Buy	BTIG Research
12/3/2024	$63.00 → $70.00	Buy	H.C. Wainwright
11/22/2024	$79.00	Outperform	Leerink Partners
10/24/2024	$69.00	Buy	UBS
9/6/2024	$70.00	Buy	Stifel
5/30/2024	$47.00	Sector Perform	Scotiabank
3/21/2024	$62.00	Buy	BTIG Research
3/20/2024	$100.00	Overweight	Cantor Fitzgerald

Amendment: SEC Form SC 13D/A filed by Janux Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$JANX

$JANX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Business Officer Meyer Andrew Hollman exercised 3,333 shares at a strike of $4.21 and sold $106,745 worth of shares (3,333 units at $32.03) (SEC Form 4)

Chief Business Officer Meyer Andrew Hollman exercised 3,334 shares at a strike of $4.21 and sold $100,020 worth of shares (3,334 units at $30.00) (SEC Form 4)

Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

$JANX
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

SEC Form 10-Q filed by Janux Therapeutics Inc.

Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$JANX
Financials

Live finance-specific insights

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

$JANX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

$JANX
Press Releases

Fastest customizable press release news feed in the world

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

$JANX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG Research reiterated coverage on Janux Therapeutics with a new price target

H.C. Wainwright reiterated coverage on Janux Therapeutics with a new price target

Leerink Partners initiated coverage on Janux Therapeutics with a new price target

$JANX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

$JANX
Leadership Updates

Live Leadership Updates

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics Announces Updates to Board of Directors

Amendment: SEC Form SC 13D/A filed by Janux Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $JANX

$JANX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Business Officer Meyer Andrew Hollman exercised 3,333 shares at a strike of $4.21 and sold $106,745 worth of shares (3,333 units at $32.03) (SEC Form 4)

Chief Business Officer Meyer Andrew Hollman exercised 3,334 shares at a strike of $4.21 and sold $100,020 worth of shares (3,334 units at $30.00) (SEC Form 4)

Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

$JANX SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

SEC Form 10-Q filed by Janux Therapeutics Inc.

Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$JANX Financials

Live finance-specific insights

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

$JANX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

$JANX Press Releases

Fastest customizable press release news feed in the world

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

$JANX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG Research reiterated coverage on Janux Therapeutics with a new price target

H.C. Wainwright reiterated coverage on Janux Therapeutics with a new price target

Leerink Partners initiated coverage on Janux Therapeutics with a new price target

$JANX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

$JANX Leadership Updates

Live Leadership Updates

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics Announces Updates to Board of Directors

Recent Analyst Ratings for
$JANX

$JANX
Insider Trading

$JANX
SEC Filings

$JANX
Financials

$JANX
Large Ownership Changes

$JANX
Press Releases

$JANX
Analyst Ratings

$JANX
Insider Purchases

$JANX
Leadership Updates